Anteris Technologies Limited (ASX: AVR) announces that the First-in-Human Study of the DurAVR Transcatheter Heart Valve (THV) revealed promising hemodynamic performance that remained consistent for up to 1 year, leading to the restoration of near-normal blood flow dynamics. Moreover, the DurAVR THV exhibited an exceptional safety profile, with no reported cases of mortality (regardless of cause), disabling stroke, life-threatening bleeding, or myocardial infarction during follow-up visits.
The DurAVR THV was implanted without any device-related complications in all 13 enrolled patients, achieving a 100% success rate. Favorable hemodynamic results inclusive of zero prosthesis-patient mismatches were observed at 6 months, and results were sustained at 1 year in patients who completed the 1-year follow-up at the time the paper was submitted. These encouraging preliminary results from the First-in-Human study are scheduled to undergo further validation through an upcoming Early Feasibility Study (EFS) approved by the FDA, which is set to commence soon.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
